Bain Capital
http://www.baincapital.comBain Capital, LLC is a global private investment firm that manages several pools of capital including private equity, venture capital, public equity and leveraged debt assets with more than $65 billion in assets under management. Since its inception in 1984, Bain Capital has made private equity investments and add-on acquisitions in more than 300 companies in a variety of industries around the world, and has a team of almost 300 professionals dedicated to investing in and supporting its portfolio companies, including such leading companies as Dunkin' Donuts, Michaels Stores and Domino's Pizza. Headquartered in Boston, Bain Capital has offices in New York, London, Munich, Hong Kong, Shanghai and Tokyo.
View Older Stories View More Recent Stories
-
VXI Recognized by Newsweek Among America's Greatest Workplaces for Inclusion
-
Silver Lake in talks to buy majority stake in Intel's Altera unit, sources say
-
Waystar Holding (WAY) Announces 18M Share Proposed Public Offering of Common Stock
-
Waystar Announces Proposed Public Offering of Common Stock
-
Cube Launches Cube Cloud for the Microsoft Enterprise
-
Hightouch Announces $80M Series C at $1.2B Valuation to Bring AI Decisioning to Marketers
-
Solid Biosciences (SLDB) Prices 35.74M Share Offering at $4.03/sh
-
Solid Biosciences Announces Pricing of Underwritten Offering
-
Britain's Airport Coordination beats Qantas-Virgin JV to manage slots in Sydney
-
Australia backs Virgin-Qatar Airways tie-up citing improved air services
-
Austrian ex-chancellor Kurz's cybersecurity firm says reaches $1 billion valuation
-
Dream, the First AI Company for National Cybersecurity, Raises $100M to Defend Nations and Critical Infrastructure
-
Bain Capital ends acquisition battle with KKR for Fuji Soft
-
Form 13F-NT Bain Capital Partners For: Dec 31
-
Form 13F-NT Bain Capital Fund XI, For: Dec 31
-
Form 13F-NT Bain Capital Fund XII, For: Dec 31
-
Form 13F-NT Bain Capital Partners For: Dec 31
-
Form 13F-HR BAIN CAPITAL INVESTORS For: Dec 31
-
Form 13F-NT Bain Capital Life Scienc For: Dec 31
-
Form 13F-NT Bain Capital Life Scienc For: Dec 31
-
Form 13F-NT Bain Capital Life Scienc For: Dec 31
-
Form 13F-HR Bain Capital Life Scienc For: Dec 31
-
Form 13F-NT Bain Capital Life Scienc For: Dec 31
-
Form 13F-NT Bain Capital Life Scienc For: Dec 31
-
Form 13F-NT Bain Capital Life Scienc For: Dec 31
-
Form 13F-NT Bain Capital Life Scienc For: Dec 31
-
Form 13F-NT Bain Capital Life Scienc For: Dec 31
-
Form SCHEDULE 13G/A Canada Goose Holdings Filed by: Bain Capital Integral Investors 2008, L.P.
-
Form SCHEDULE 13G/A Annexon, Inc. Filed by: Bain Capital Life Sciences Fund, L.P.
-
Form SCHEDULE 13G/A Disc Medicine, Inc. Filed by: Bain Capital Life Sciences Opportunities III, LP
-
Form 13F-NT Bain Capital Venture For: Dec 31
-
Form 13F-HR BAIN CAPITAL VENTURE For: Dec 31
-
Form 13F-NT Bain Capital Venture For: Dec 31
-
Form 13F-NT Bain Capital Venture For: Dec 31
-
Form 13F-NT Bain Capital Venture For: Dec 31
-
Form 13F-HR Bain Capital Public Equi For: Dec 31
-
Form 13F-HR Bain Capital Public Equi For: Dec 31
-
Form 13F-HR Bain Capital Credit, LP For: Dec 31
-
Bain Capital Credit Announces $6 Billion of Financing Investments for 2024
-
Thryv (THRY) promotes Cameron Lessard to VP of Corporate Development and Strategy
-
Thryv Promotes Cameron Lessard to Vice President of Corporate Development and Strategy
-
Veza Strengthens Channel Strategy and Accelerates Global Go-to-Market Efforts with Ecosystems Leadership
-
Broad Street Development Expands Investment Capabilities with New Executive Hires; Plans to Acquire $2B in Assets
-
Bio-IT World Venture, Innovation & Partnering Conference Returns to Boston April 3, 2025 with Expanded AI Focus
-
Exclusive-Buyout firms vie for cybersecurity firm Trend Micro, sources say
-
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
-
Payments Technology Leader Orum Launches ‘Monitor’ – The First-Ever Payments Portal Purpose Built To Optimize & Orchestrate Payment Operations For Enterprise Businesses
-
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
-
Alkeus Pharmaceuticals Announces Two Presentations of Oral Gildeuretinol Data During the 48th Annual Meeting of the Macula Society Being Held February 12-15, 2025
-
Bain Capital says it may withdraw tender offer proposal for Fuji Soft
